Skip to content

Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness

Anatomical Resection Versus Nonanatomical Resection for Colorectal Liver Metastases Patients With Gene Mutation or Right-sidedness: The ARCLAMP Randomized Controlled Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05881746
Enrollment
176
Registered
2023-05-31
Start date
2023-07-01
Completion date
2028-07-01
Last updated
2023-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Carcinoma, Liver Metastases

Brief summary

In this study, colorectal cancer patients with initially resectable liver-only metastases, as prospectively confirmed by a local multidisciplinary team (MDT) according to predefined criteria, will be tested for RAS and BRAF tumor mutation status. Patients with gene mutant or right-sidedness will be randomised between anatomical resection (AR) or nonanatomical resection (NAR). The primary end-point is the relapse-free survival.

Detailed description

This study is a prospective, single-center, randomized control trial. The major including criteria are (1) Histologically confirmed colorectal cancer initially resectable liver-only metastases ; (2) patient has the opportunity to perform either anatomical resection (AR) or nonanatomical resection (NAR) surgery; (3) the number of metastasis is 1-3; (4) KRAS/NRAS/BRAF mutation or right-sidedness. Patients will be randomised between AR or NAR. Patients will be stratified for gene mutation and right-sidedness. Based upon the segmental anatomy of the liver according to Couinaud system, AR is defined as the resection of one or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination thereof. NAR, also called as wedge resection, is defined as the resection of the tumor with a margin of normal parenchyma regardless of the hepatic anatomy. The primary end-point is the relapse-free survival. The secondary end-points are postoperative complication, postoperative mortality, hospital length of stay, and overall survival.

Interventions

Based upon the segmental anatomy of the liver according to Couinaud system, anatomical resection (AR) was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these.

PROCEDUREnonanatomical liver resection

Nonanatomical resection(NAR), known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.

Sponsors

Fudan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Age ≥ 18 and ≤ 75 years; 2. Histological proof of colorectal adenocarcinoma; 3. Resectable colorectal liver metastasis without detectable extrahepatic distant metastatic disease (determined by a local MDT); 4. Suitable for anatomical or nonanatomical liver resection (determined by a local MDT); 5. Number of metastasis is 1 to 3; 6. KRAS/NRAS/BRAF mutation or right-sidedness; 7. Performance Status (ECOG) 0\ 1; 8. Adequate hematological function: Neutrophils≥1.5 x109/l and platelet count≥100 x109/l; Hb ≥9g/dl (within 1 week prior to randomization); 9. Adequate liver and renal function: total bilirubin ≤2.0 mg/dl, serum transaminases ≤ 5x upper limit of normal(ULN), and serum creatinine ≤ 1.5x ULN and creatinine clearance ≥ 30 ml/min; 10. Written informed consent.

Exclusion criteria

1. Previous systemic treatment for metastatic disease; 2. Previous surgery for metastatic disease; 3. Extrahepatic metastases; 4. Unresectable primary tumor; 5. Major cardiovascular events (myocardial infarction, severe/unstable angina, congestive heart failure, CVA) within 12 months before randomisation; 6. Second primary malignancy within the past 5 years; 7. Acute or subacute intestinal obstruction; 8. Drug or alcohol abuse; 9. No legal capacity or limited legal capacity; 10. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frameDescription
relapse-free survival3 yearsThe relapse-free survival (PFS) was defined as the period from the start of initial liver resection to the date of tumor relapse or death

Secondary

MeasureTime frameDescription
overall survival5 yearsThe overall survival (OS) was defined as the period from the start of initial liver resection until death from any cause, at which point the data was censored.
postoperative hospital stay30 days post operativelyThe postoperative hospital stay is defined as the number of date from the first day after operation to discharge.
postoperative complicationAfter surgery during one monthPatients will be evaluated for surgical morbidity during 1 month. Postoperative morbidity will be scored according 'Clavien-Dindo Grade'.
postoperative mortalityAfter surgery during 90 daysany death occured within 90 days after the last resection of primary and metastatic lesions

Countries

China

Contacts

Primary ContactJianmin Xu, MD
xujmin@aliyun.com86-18917982975
Backup ContactYijiao Chen, MD
13636443958@163.com86-13636443958

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026